Loading comparison data...
Medical Disclaimer: This site provides informational comparisons only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your physician or pharmacist before making medication decisions.
Compare Ozanimod (Zeposia) and Tofacitinib (Xeljanz) — clinical data, side effects, and patient experiences.
Zeposia · S1P Receptor Modulator
How it works
S1P receptor 1,5 modulator that reduces circulating lymphocytes by retaining them in lymph nodes.
Approved for
Xeljanz · JAK Inhibitor
How it works
Inhibits Janus kinases JAK1 and JAK3, modulating the signalling of interleukins and interferons involved in immune and inflammatory pathways.
Approved for
Estimated frequency (%) based on clinical trial data
No specific warnings
No head-to-head clinical studies found for Ozanimod vs Tofacitinib.
Ozanimod is a S1P Receptor Modulator, while Tofacitinib belongs to the JAK Inhibitor class. This means they work through different pharmacological mechanisms, which may influence both efficacy and side effect profiles.
Both medications are approved for Ulcerative Colitis. When two drugs treat the same condition, the choice between them often depends on the patient's medical history, other medications, tolerability, and prescriber preference.
Tofacitinib carries 2 FDA warnings. Patients should discuss all warnings and contraindications with their healthcare provider before starting or switching medications..
This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.